Society Logo
ME/CFS Australia Ltd
Please click here to donate ME/CFS South Australia Inc
 
 
Facebook
 
ME/CFS SOUTH AUSTRALIA INC

Registered Charity 3104

Email:
sacfs@sacfs.asn.au

Mailing address:

PO Box 322,
Modbury North,
South Australia 5092

Phone:
1300 128 339

Office Hours:
Monday - Friday,
10am - 4pm
(phone)

ME/CFS South Australia Inc supports the needs of sufferers of Myalgic Encephalomyelitis, Chronic Fatigue Syndrome and related illnesses. We do this by providing services and information to members.

Disclaimer

ME/CFS South Australia Inc aims to keep members informed of various research projects, diets, medications, therapies, news items, etc. All communication, both verbal and written, is merely to disseminate information and not to make recommendations or directives.

Unless otherwise stated, the views expressed on this Web site are not necessarily the official views of the Society or its Committee and are not simply an endorsement of products or services.

Become a Member
DOCX Application Form (Word, 198 KB)
Why become a member?

Systems Pathology Of Neuropathic Pain And Fibromyalgia

Monday 25 November 2019

 

From medical journal the Biological and Pharmaceutical Bulletin:

 

Neuroscience
 

Systems Pathology of Neuropathic Pain and Fibromyalgia

By Hiroshi Ueda
2019 Volume 42 Issue 11 Pages 1773-1782
© 2019 The Pharmaceutical Society of Japan.

Abstract

Currently, only a few medicines have been approved for use in the clinical treatment of chronic pain, but they are not fully satisfying due to their side effects.

From the view that radical treatment, rather than simply treating symptoms, is more important in addressing life-long chronic pain, we have been investigating translational research for a mechanism-based medicine to treat pain.

Through the characterization of various types of peripheral and central neuropathic pain in mice, we discovered that lysophosphatidic acid (LPA) plays roles in definitive mechanisms of the development and maintenance of neuropathic pain.

We found LPA1 receptor- and LPA3 receptor-mediated amplification of LPA production could be a key mechanism underlying the initiation and maintenance of this pain.

We have developed stress-induced fibromyalgia models, and have revealed that LPA1 receptor-signaling also plays key roles in the mechanism.

Throughout these studies, we found that LPA plays a key role in pain memory, and that LPA1 receptor- and LPA3 receptor-antagonists could reverse the established pain, and thereby cure the disease source of pain.

 

Full article…

 


Arrow right

More Fibromyalgia News

 


 

blog comments powered by Disqus
Previous Previous Page